Immix Total Cash From Financing Activities from 2010 to 2024

IMMX Stock  USD 2.11  0.14  7.11%   
Immix Biopharma Total Cash From Financing Activities yearly trend continues to be fairly stable with very little volatility. Total Cash From Financing Activities will likely drop to about 12.6 M in 2024. During the period from 2010 to 2024, Immix Biopharma Total Cash From Financing Activities regression line of annual values had r-squared of  0.46 and arithmetic mean of  5,302,067. View All Fundamentals
 
Total Cash From Financing Activities  
First Reported
2010-12-31
Previous Quarter
15.5 M
Current Value
12.6 M
Quarterly Volatility
7.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Immix Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immix Biopharma's main balance sheet or income statement drivers, such as Tax Provision of 12.5 K, Net Interest Income of 360.6 K or Depreciation And Amortization of 3 K, as well as many indicators such as Dividend Yield of 0.0, Ptb Ratio of 7.68 or Book Value Per Share of 0.98. Immix financial statements analysis is a perfect complement when working with Immix Biopharma Valuation or Volatility modules.
  
Check out the analysis of Immix Biopharma Correlation against competitors.
For more information on how to buy Immix Stock please use our How to Invest in Immix Biopharma guide.

Latest Immix Biopharma's Total Cash From Financing Activities Growth Pattern

Below is the plot of the Total Cash From Financing Activities of Immix Biopharma over the last few years. It is Immix Biopharma's Total Cash From Financing Activities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immix Biopharma's overall financial position and show how it may be relating to other accounts over time.
Total Cash From Financing Activities10 Years Trend
Slightly volatile
   Total Cash From Financing Activities   
       Timeline  

Immix Total Cash From Financing Activities Regression Statistics

Arithmetic Mean5,302,067
Geometric Mean2,348,882
Coefficient Of Variation134.24
Mean Deviation5,945,423
Median1,050,000
Standard Deviation7,117,309
Sample Variance50.7T
Range17.8M
R-Value0.68
Mean Square Error29.3T
R-Squared0.46
Significance0.01
Slope1,082,489
Total Sum of Squares709.2T

Immix Total Cash From Financing Activities History

202412.6 M
202315.5 M
20223.2 M
202018.8 M

About Immix Biopharma Financial Statements

Immix Biopharma investors use historical fundamental indicators, such as Immix Biopharma's Total Cash From Financing Activities, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immix Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Cash From Financing Activities15.5 M12.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Immix Stock Analysis

When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.